Form 4: Stoke Therapeutics Director's Equity Grant

Stoke Therapeutics Director Edward M. Kaye received a new grant of 52,500 performance stock units and acquired 26,250 common shares through vesting.

Summary

• Director Edward M. Kaye acquired 26,250 shares of common stock on August 14, 2025, resulting from the vesting and conversion of previously granted performance stock units.
• Kaye's direct beneficial ownership of common stock increased to 165,596 shares following this transaction.
• Concurrently, Kaye was granted a new award of 52,500 Performance Stock Units (PSUs) on August 14, 2025.
• Each PSU represents a right to receive one share of the Issuer's common stock.
• This new PSU award is a grant of restricted stock units contingent on the achievement of certain performance criteria, as certified by the Issuer's compensation committee.
• Half of this new PSU award (26,250 units) is scheduled to vest on August 14, 2025, and the remaining half (26,250 units) is scheduled to vest on August 14, 2026, subject to Kaye's continued service.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant and vesting for a director, which is generally positive as it aligns insider interests with company performance and retention. No negative financial or operational news is present.

Positives

• Director Edward M. Kaye received a new grant of 52,500 Performance Stock Units, aligning his interests with long-term company performance and incentivizing continued service.
• The vesting of 26,250 previously granted performance stock units into common shares increases the director's direct ownership, which can be viewed as a positive signal of commitment.
• The equity grants are tied to performance criteria, indicating a focus on achieving strategic objectives.

Risks

• The vesting of both the newly granted and previously granted performance stock units is contingent on the reporting person's continued service to the Issuer, meaning the full benefit is not guaranteed if service ceases.
• The specific performance criteria for the new PSU grant are not detailed, introducing uncertainty regarding the full realization of the award.

Future Outlook

The future outlook indicates that half of the newly granted performance stock units will vest on August 14, 2026, contingent on the director's continued service, suggesting a long-term incentive structure.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industries, where equity grants like Performance Stock Units are commonly used to align management incentives with shareholder value and long-term company performance. Such grants are typical for directors in growth-oriented sectors like biotech.

Comparison to Industry Standards

• Equity grants to directors, particularly in the form of performance-based units, are a common compensation mechanism across the biotechnology sector.
• Companies like Moderna (MRNA) or BioNTech (BNTX) frequently utilize similar long-term incentive plans to retain key talent and align interests.
• The specific grant size of 52,500 PSUs for a director at Stoke Therapeutics (STOK) would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess its relative size and competitiveness.
• The vesting schedule, with a portion vesting in 2025 and the remainder in 2026, is a standard multi-year vesting approach seen in many public companies to encourage sustained commitment.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with long-term shareholder value through equity grants. Potential for dilution from future share issuance upon PSU vesting.

Next Steps

• Continued service of Edward M. Kaye to Stoke Therapeutics, Inc. for the remaining PSU vesting.
• Vesting of the remaining 26,250 Performance Stock Units on August 14, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant and vesting for a director, which is a standard compensation event and does not provide new fundamental information to warrant a change in investment recommendation. It aligns insider interests but doesn't signal a significant shift in company prospects or valuation.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Director Compensation, Performance Stock Units, Equity Grant, Restricted Stock Units, Biotechnology, Pharmaceuticals